Katwijk gives green light: US multibillion-dollar obesity drug plant approved
The municipality of Katwijk has approved the construction of a large-scale Eli Lilly pharmaceutical factory focused on obesity and diabetes medication. The project is supported by a 100 million euro government deal to improve local infrastructure and housing, though it faces ongoing scrutiny over high water and energy consumption.
The municipality of Katwijk has approved the construction of a massive multibillion-euro pharmaceutical factory by the American company Eli Lilly. Located near the Leiden Bio Science Park at the Valkenburgse Meer, the facility will focus on producing diabetes and obesity medications. The project, which spans the equivalent of 28 football fields, is expected to provide employment for over 500 people. To secure the project, local authorities negotiated a 100 million euro deal with the government to address regional traffic infrastructure and housing affordability. Eli Lilly selected the site over sixty other European locations, citing the proximity to major transport hubs and scientific institutions like the European Medicines Agency in Amsterdam.
Despite the economic benefits, the project has faced scrutiny regarding its significant utility demands. The factory is projected to consume one million liters of water daily and requires substantial electricity, necessitating the temporary use of natural gas-powered turbines due to local grid capacity constraints. While residents expressed concerns regarding environmental impact and property values, city officials maintained that stringent safety standards are in place for the facility.
Based on reporting by nu. Translated and condensed by LocalHeadlines.
